# Rekvina Labs (NSE: VINRKLB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/VINRKLB · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹22 Cr, it ranks 3552nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 0.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹1 Cr and net profit −₹0 Cr, on a standalone basis. Promoters held 41.30% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹22 Cr |
| ROE | 0.0% (FY25) |
| ROCE | 41.3% (FY25) |
| Debt to equity | -0.74 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹1 Cr | — | −₹0 Cr | — | −₹0.10 |
| Q3 FY26 | ₹0 Cr | — | −₹0 Cr | — | −₹0.21 |
| Q2 FY26 | ₹0 Cr | — | −₹0 Cr | — | −₹0.06 |
| Q1 FY26 | — | — | −₹0 Cr | — | −₹0.06 |
| Q4 FY25 | — | — | −₹0 Cr | — | −₹0.07 |
| Q3 FY25 | — | — | −₹0 Cr | — | −₹0.04 |
| Q2 FY25 | — | — | −₹0 Cr | — | −₹0.11 |
| Q1 FY25 | — | — | ₹0 Cr | — | ₹0.00 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹0 Cr | −₹0 Cr |
| FY24 | ₹0 Cr | −₹0 Cr |
| FY23 | ₹0 Cr | ₹0 Cr |
| FY22 | ₹0 Cr | −₹0 Cr |
| FY21 | ₹0 Cr | −₹0 Cr |
| FY20 | ₹0 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 41.30%
- Non-institutions: 58.70%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [SUPHA PHARMACHE](https://app.pivotnow.in/stock/SUPHA) | — | ₹25 Cr | — | — |
| [Transgene Biote](https://app.pivotnow.in/stock/TRABI) | — | ₹23 Cr | — | — |
| [Hamps Bio](https://app.pivotnow.in/stock/HAMPS) | — | ₹22 Cr | — | — |
| [Adeshwar Medite](https://app.pivotnow.in/stock/ADESHWAR) | — | ₹21 Cr | — | — |
| [Maitri](https://app.pivotnow.in/stock/MAITRI) | — | ₹19 Cr | — | — |
| [Desh Rakshak](https://app.pivotnow.in/stock/DESHRAK) | — | ₹19 Cr | — | — |

## Questions and answers

### What is the market cap of Rekvina Labs?

Rekvina Labs' market capitalisation is ₹22 Cr (₹22 Cr) at the 22 Oct 2026 close, ranking 3552nd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Rekvina Labs?

Return on equity was 0.0% in FY25 and return on capital employed was 41.3% in FY25 (standalone figures).

### Is Rekvina Labs a debt-free company?

Rekvina Labs is close to debt-free: its debt-to-equity ratio was -0.74 in FY25.

### What were Rekvina Labs' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Rekvina Labs reported revenue of ₹1 Cr and net profit of −₹0 Cr.

### What is the shareholding pattern of Rekvina Labs?

As of 30 Jun 2026: promoters 41.30%, non-institutions 58.70%.

### Who are Rekvina Labs' competitors?

The listed Pharma & Healthcare companies closest to Rekvina Labs by market cap are SUPHA PHARMACHE, Transgene Biote, Hamps Bio, Adeshwar Medite, Maitri and Desh Rakshak.

### Is Rekvina Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Rekvina Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VINRKLB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.